Intermittent androgen suppression for rising PSA level

New England Journal of Medicine

Volumn 367, Issue 23, 2012, Pages 2252-2253

  Kelly, Ciara ^a   Kelly, Paul ^a   O'Reilly, Seamus ^a  

^a University College Cork   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL TUMOR; GERM CELL TUMOR; HUMAN; LETTER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; THERAPY EFFECT;

EID: 84870515526     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1211950     Document Type: Letter

References (5)

1. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895-903.
2. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24:1868-76.
3. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumour markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
4. Lange PH, McIntire KR, Waldmann TA, Hakala TR, Fraley EE. Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germcell testicular cancer. N Engl J Med 1976;295:1237-40.
5. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.